Towards the development of an off-the-shelf cure for cancer

This Clarity Insight was an early attempt to look at the conditions necessary for off-the-shelf cell therapies. This was motivated by the approval of autologous CAR-T products, which then saw a flurry of activities to bring the first allogeneic CAR-T to market. This Insight briefly touches on some critical issues such as cryopreservation.